| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPPI | Common Stock, $0.001 par value | Award | $0 | +405K | +50.11% | $0.00 | 1.21M | Jun 21, 2022 | Direct | F1 |
| holding | SPPI | Common Stock, $0.001 par value | 14.1K | Jun 21, 2022 | By 401(k) plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPPI | Stock Option (Right to Buy) | Award | $0 | +1.08M | $0.00 | 1.08M | Jun 21, 2022 | Common Stock | 1.08M | $0.63 | Direct | F2, F3, F4 | |
| transaction | SPPI | Stock Option (Right to Buy) | Award | $0 | +1.49M | $0.00 | 1.49M | Jun 21, 2022 | Common Stock | 1.49M | $0.63 | Direct | F2, F4, F5 |
| Id | Content |
|---|---|
| F1 | The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022. |
| F2 | The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022. |
| F3 | Represents options granted in connection with the reporting person's promotion to President and Chief Executive Officer. |
| F4 | One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively. |
| F5 | Represents the annual performance awards granted to the reporting person. |